Japan's Ruling Party Considers New Drug Administrative Body
This article was originally published in PharmAsia News
Executive Summary
Facing the aftermath of the hepatitis C scandal, Japan's ruling Liberal Democratic Party organized a discussion panel on pharmaceutical policy, and the panel has proposed to establish a new administrative entity to oversee drug approval and adverse effects prevention. Currently, the Ministry of Health, Labor and Welfare, and the Pharmaceuticals and Medical Device Agency are in charge of drug review, approval and safety measures. The LDP panel is proposing to establish an independent drug administrative agency that is separate from MHLW, functioning like a Japanese version of U.S. FDA. (Click here for more - Japanese language